185 related articles for article (PubMed ID: 22490522)
21. Inhibition of MKK7-JNK by the TOR signaling pathway regulator-like protein contributes to resistance of HCC cells to TRAIL-induced apoptosis.
Song IS; Jun SY; Na HJ; Kim HT; Jung SY; Ha GH; Park YH; Long LZ; Yu DY; Kim JM; Kim JH; Ko JH; Kim CH; Kim NS
Gastroenterology; 2012 Nov; 143(5):1341-1351. PubMed ID: 22841785
[TBL] [Abstract][Full Text] [Related]
22. Caveolin-1 Confers Resistance of Hepatoma Cells to Anoikis by Activating IGF-1 Pathway.
Tang W; Feng X; Zhang S; Ren Z; Liu Y; Yang B; lv B; Cai Y; Xia J; Ge N
Cell Physiol Biochem; 2015; 36(3):1223-36. PubMed ID: 26138883
[TBL] [Abstract][Full Text] [Related]
23. A new xanthatin analogue 1β-hydroxyl-5α-chloro-8-epi-xanthatin induces apoptosis through ROS-mediated ERK/p38 MAPK activation and JAK2/STAT3 inhibition in human hepatocellular carcinoma.
Fang XY; Zhang H; Zhao L; Tan S; Ren QC; Wang L; Shen XF
Biochimie; 2018 Sep; 152():43-52. PubMed ID: 29960031
[TBL] [Abstract][Full Text] [Related]
24. PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer.
Zhuang J; Song Y; Ye Y; He S; Ma X; Zhang M; Ni J; Wang J; Xia W
J Transl Med; 2019 Oct; 17(1):343. PubMed ID: 31619254
[TBL] [Abstract][Full Text] [Related]
25. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma.
Park SY; Han J; Kim JB; Yang MG; Kim YJ; Lim HJ; An SY; Kim JH
Eur J Cancer; 2014 Jan; 50(2):341-50. PubMed ID: 24161763
[TBL] [Abstract][Full Text] [Related]
27. OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway.
Li H; Miao Q; Xu CW; Huang JH; Zhou YF; Wu MJ
J Korean Med Sci; 2016 Aug; 31(8):1215-23. PubMed ID: 27478331
[TBL] [Abstract][Full Text] [Related]
28. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.
Zuo M; Li C; Lin J; Javle M
Oncotarget; 2015 May; 6(13):10940-9. PubMed ID: 25883212
[TBL] [Abstract][Full Text] [Related]
29. Decrease of MLK4 prevents hepatocellular carcinoma (HCC) through reducing metastasis and inducing apoptosis regulated by ROS/MAPKs signaling.
Li Y; Zuo H; Wang H; Hu A
Biomed Pharmacother; 2019 Aug; 116():108749. PubMed ID: 31071576
[TBL] [Abstract][Full Text] [Related]
30. FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via Akt signaling in hepatocellular carcinoma.
Zhang ZQ; Chen J; Huang WQ; Ning D; Liu QM; Wang C; Zhang L; Ren L; Chu L; Liang HF; Fan HN; Zhang BX; Chen XP
Mol Oncol; 2019 Apr; 13(4):792-810. PubMed ID: 30556279
[TBL] [Abstract][Full Text] [Related]
31. [The role of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance of hepatocellular carcinoma].
Zhu H; Chen XP; Luo SF; Guan J; Zhang WG; Zhang BX; Mao CP
Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(13):917-20. PubMed ID: 17953842
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling.
Lee EK; Kim HJ; Lee KJ; Lee HJ; Lee JS; Kim DG; Hong SW; Yoon Y; Kim JS
Int J Oncol; 2011 Feb; 38(2):325-33. PubMed ID: 21132267
[TBL] [Abstract][Full Text] [Related]
33. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors.
Yoshida T; Hisamoto T; Akiba J; Koga H; Nakamura K; Tokunaga Y; Hanada S; Kumemura H; Maeyama M; Harada M; Ogata H; Yano H; Kojiro M; Ueno T; Yoshimura A; Sata M
Oncogene; 2006 Oct; 25(45):6056-66. PubMed ID: 16652141
[TBL] [Abstract][Full Text] [Related]
34. Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation.
Sun CK; Man K; Ng KT; Ho JW; Lim ZX; Cheng Q; Lo CM; Poon RT; Fan ST
Carcinogenesis; 2008 Nov; 29(11):2096-105. PubMed ID: 18765415
[TBL] [Abstract][Full Text] [Related]
35. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
37. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
39. STEAP3 promotes cancer cell proliferation by facilitating nuclear trafficking of EGFR to enhance RAC1-ERK-STAT3 signaling in hepatocellular carcinoma.
Wang LL; Luo J; He ZH; Liu YQ; Li HG; Xie D; Cai MY
Cell Death Dis; 2021 Nov; 12(11):1052. PubMed ID: 34741044
[TBL] [Abstract][Full Text] [Related]
40. Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.
Dong C; Zhao B; Long F; Liu Y; Liu Z; Li S; Yang X; Sun D; Wang H; Liu Q; Liang R; Li Y; Gao Z; Shao S; Miao QR; Wang L
Oncotarget; 2016 Feb; 7(8):8850-65. PubMed ID: 26840457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
